Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020672 (
hypothermia
)
17,327
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The tripeptide, prolyl-leucyl glycine amide, a melanocyte-stimulating hormone inhibitory factor (
MIF-I
), which has been reported to be effective in improving symptoms of Parkinson's disease, has been compared with drugs known to activate dopamine receptors in rat and mouse brain. Unlike apomorphine, amphetamine and amantadine it was incapable of producing sterotyped behaviour in the rat and unlike 1-dopa it was also ineffective in rats pretreated with the monoamineoxidase inhibitor mebanazine. Neither did it potentiate apomorphine nor amphetamine in this test.
MIF-I
did not antagonise chlorpromazine-induced loss of locomotor activity in mice, an effect which was antagonised by apomorphine, amphetamine and amantadine. Chlorpromazine
hypothermia
in the mouse was antagonised by 1-dopa but not by
MIF-I
; similar findings were obtained in reserpine-pretreated mice. These results suggest that the reported beneficial effect of
MIF-I
in Parkinson's disease is unlikely to be due to an interaction with dopamine systems in the brain.
...
PMID:A comparison between a melanocyte-stimulating hormone inhibitory factor (MIF-I) and substances known to activate central dopamine receptors. 0 32
The daily pretreatment of rats with oxytocin (OXY) or
MIF-I
prior to ethanol (Et-OH) administration markedly altered the alcohol tolerance when tested on the fifth day of treatment. OXY (800 and 2400 nmole/kg SC) and MIF (800 nmole/kg SC) inhibited the development of tolerance to the hypnotic effect of Et-OH. MIF at this dose also inhibited the tolerance to the hypothermic effect. Only OXY in the dose of 800 nmole/kg suppressed
hypothermia
in an acute experiment with Et-OH and produced by itself
hypothermia
after acute administration (2400 nmole/kg). The tolerance to this last effect developed after four days of peptide treatment. The results indicate that OXY and
MIF-I
can influence the processes of development of tolerance to some central depressive effects of Et-OH in rats.
...
PMID:The effect of oxytocin and fragment (MIF-I) on the development of tolerance to hypothermic and hypnotic action of ethanol in the rat. 285 73
Experiments on cats revealed an emotiotropic action of melanostatin on the original spectrum of emotional reactivity, similar to the effects of L-DOPA and amantadin. The drug does not possess an antidepressant action proper but activates the aggressive-defensive behaviour in experimental reserpine depression and reduces the provocation-induced aggressive behaviour in experimental haloperidol depression. In reserpinized mice, it antagonizes reserpine
hypothermia
, increases muscle tone and eliminates ptosis. It decreases haloperidol-induced catalepsia.
Melanostatin
increases the brain level of dopamine and its metabolite, homovanilic acid.
...
PMID:[Psychopharmacologic spectrum of melanostatin]. 610 96
Administration of several doses of
MIF-I
or alpha-MSH did not modify colonic temperature or the level of motor activity of rats in ambient temperatures of 4 degree or 20 degrees C. However, the thermoregulatory but not motor effects of the interaction between
MIF-I
or alpha-MSH with d-amphetamine were dependent upon ambient temperature. At 4 degree C, 1.0 mg/kg of both peptides enhanced the d-amphetamine-induced
hypothermia
, but at 20 degrees C both peptides blocked the hyperthermic effects of d-amphetamine. The hypothermic effect of chlorpromazine (CPZ) at 4 degree C and 20 degrees C was blocked by 1.0 mg/kg
MIF-I
but not by 1.0 mg/kg alpha-MSH. No linear dose response relationships between various doses of
MIF-I
or alpha-MSH and thermal responses were found. Administration of melanin or the use of hypophysectomized rats did not alter the significant interactions observed after peripheral injections.
...
PMID:Interaction of MIF-I or alpha-MSH with D-amphetamine or chlorpromazine on thermoregulation and motor activity of rats maintained at different ambient temperatures. 611 34
The effects of beta-endorphin,
MIF-I
, and alpha-MSH on d-amphetamine- a CPZ-induced hypothermias in rats kept at 4 degrees C were tested in three experimental groups: (a) intact; (b) rats with lesions of the olfactory tubercle; and (c) rats in which the link between the DA mesolimbic pathway and the striatum was disconnected. All drugs tested alone (except
MIF-I
) caused significant
hypothermia
. Pretreatment with CPZ,
MIF-I
, and alpha-MSH potentiated d-amphetamine-induced
hypothermia
in intact rats. Pretreatment with alpha-MSH potentiated CPZ-induced
hypothermia
. beta-Endorphin partially blocked d-amphetamine-induced
hypothermia
, but did not interact with CPZ,
MIF-I
, or alpha-MSH. All potentiations were either reduced or disappeared in the incisioned rats. CPZ and alpha-MSH caused
hypothermia
in olfactory tubercle-lesioned rats. The results indicate that: (a) the DA mesolimbic pathway is involved in the hypothermic response of all drugs tested; (b) an intact feedback loop is required for the potentiation of the hypothermic response of CPZ on d-amphetamine,
MIF-I
on d-amphetamine, and alpha-MSH on d-amphetamine and CPZ; (c) beta-endorphin acts as a partial blocker of d-amphetamine;
MIF-I
is a weak potentiator of d-amphetamine, alpha-MSH acts as a negative modulator of the DA system, most probably in the striatum.
...
PMID:Modification of d-amphetamine- or chlorpromazine-induced hypothermia by beta-endorphin, MIF-I, and alpha-MSH: mediation by the dopaminergic system. 612 51
Neurotensin (NT), an endogenous tridecapeptide, produces significant
hypothermia
after intracisternal (i.c.) or intracerebroventricular (i.c.v.) administration in microgram quantities in a variety of laboratory animals. The present study sought to clarify the mechanism of the hypothermic action by utilizing pharmacological treatments which alter the function of brain neurotransmitter systems. Pretreatment of rats with anti-muscarinic (atropine), anti-noradrenergic (propranolol, a beta-blocker; phenoxybenzamine, an alpha-blocker) or anti-opiate (naloxone) agents did not significantly alter NT-induced
hypothermia
. Similarly depletion of brain serotonin (5-HT) with parachlorophenylalanine did not affect NT-induced
hypothermia
. However, depletion of brain catecholamine content with 6-hydroxydopamine resulted in a significant potentiation of NT-induced
hypothermia
as did pretreatment with haloperidol, a dopamine (DA) receptor antagonist. Furthermore, in rats with selective depletions of brain DA, but not norepinephrine (NE), NT-induced
hypothermia
was significantly augmented. Thus an interaction between brain DA systems and NT appears likely. These data indicate that NT-induced
hypothermia
is not dependent on intact functional activity of NE, 5-HT, muscarinic ACh or endogenous opiate systems but suggests interactions between brain DA circuits and NT. In other experiments, NT-induced
hypothermia
was found to be antagonized significantly by i.c. injection of thyrotropin-releasing hormone (TRH), but not by pretreatment with L-triiodothyronine. Another endogenous tripeptide (Pro--Leu--Gly--NH2,
MIF-I
) had no effect. Thyroidectomy (THX) significantly potentiated NT-induced
hypothermia
; NT administered i.c. significantly reduced the high serum TSH levels of THX rats. Thus, NT and TRH, two endogenous peptides, appear to be antagonists in certain systems.
...
PMID:Neurotensin-induced hypothermia: evidence for an interaction with dopaminergic systems and the hypothalamic--pituitary--thyroid axis. 644 51